

cryoprecipitate was given instead. After the completion of the pre-pregnancy assessments, starting 3 months before the planned pregnancy and continuing for the whole pregnancy and for 3 months after birth, 25 units/kg plasma-derived concentrate at a dose of 25 units/kg was applied each time and every two weeks, and in cases where this could not be provided, the follow-up was continued by applying cryoprecipitate at a dose of 5 units / kg instead. During this whole process, FXIII levels ranged between 70% and 100%. The patient, who developed an abortion risk due to decidual bleeding in the first trimester, was hospitalized and an additional 25 units / kg plasma-derived FXIII concentrate was administered and a parenteral dose of 30 mg / kg tranexamic acid was applied until the signs of decidual bleeding disappeared. An additional 50 units/kg dose of plasma-derived FXIII concentrate was administered to the patient 30 minutes before birth who had a planned delivery by cesarean section at 38 weeks of gestation, and 30 mg/kg parenteral tranexamic acid was administered for 7 days following the delivery. FXIII level was detected 50% in the child of a healthy, 3500-g born boy. The patient and her baby, who are in the first year after birth, are followed up without any complications, and prophylactic plasma-derived FXIII concentrate or cryoprecipitate is administered to the patient once a month. **Discussion and Conclusion:** Inherited bleeding diathesis lead to an increased risk of bleeding and abortion in obstetric patients. Factor XIII deficiency is an extremely rare type among them. FXIII has a role in angiogenesis as well as hemostasis. Therefore, wound healing and tissue repair are impaired in Factor XIII deficiency. The risk of premature separation of the placenta, miscarriage especially in the first trimester, and postpartum uterine bleeding are increased in FXIII deficiency. Tranexamic acid can be used safely in obstetric patients with bleeding diathesis. It may be possible to ensure that patients with factor XIII deficiency have an uncomplicated pregnancy and delivery with regular follow-ups, regular prophylactic factor preparations, plasma replacements if they are not found, and in cases of bleeding, with additional doses of factor preparations or plasma replacement applications with tranexamic acid.

<https://doi.org/10.1016/j.htct.2021.10.1066>

PP 57

EVALUATION OF THE FREQUENCY OF ARTERIAL AND VENOUS THROMBOSIS AND PREDISPOSING FACTORS IN PATIENTS USING ELTROMBOPAG

Derya Deniz Kurekci, Melda Isevi, Engin Kelkitli, Mehmet Turgut

19 Mayıs University Department of Hematology

Objective: Eltrombopag is a small molecule thrombopoietin-receptor agonist used orally for the treatment. There is a high risk of thrombosis associated with the use of Eltrombopag. Our aim in this study is evaluating the incidence of arterial and venous thrombosis in patients using Eltrombopag and

followed up in our center with the diagnosis of ITP, MDS and aplastic anemia, and contributing to the literature with the data of Central Black Sea by retrospectively evaluating the predisposing factors. **Methodology:** In this study, the data of 144 patients who were treated with Eltrombopag with the diagnosis of ITP, MDS and aplastic anemia at Ondokuz Mayıs University Faculty of Medicine Hematology Clinic between 2009-2019 were analyzed retrospectively. The data of the patients were obtained retrospectively from the hospital management information system. **Results:** The study included 144 patients who treated with Eltrombopag. 66 (45.8%) of the patients were male and 78 (54.2%) were female. The mean age of the patients was 54.12 ± 20.08 years. 102 (70.8%) of the patient were diagnosed with ITP, 31 (21.5%) with aplastic anemia and 12 (7.6%) with MDS. Thrombosis was observed in 7 (4.9%) of 144 patients who treated with Eltrombopag. Venous thrombosis was found in 6 (4.2%) of these patients and arterial thrombosis was found in one patient (0.7%). **Conclusion:** Eltrombopag treatment poses a risk for thromboembolic events. The treatment process should be followed closely especially in patients with known risk factors for thrombosis.

<https://doi.org/10.1016/j.htct.2021.10.1067>

PP 58

ETIOLOGY, TREATMENT AND FOLLOW-UP OF THROMBOSIS IN CHILDREN, ONE CENTER PROSPECTIVE TRIAL

Yunus Murat Akcabelen¹, Volkan Köse¹, Dilek Gürlek Gökçebay¹, Turan Bayhan¹, Neşe Yaralı², Namık Yaşar Özbek¹

¹ University of Health Sciences, Ankara City Hospital, Pediatric Hematology and Oncology

² Ankara Yıldırım Beyazıt University Ankara City Hospital, Pediatric Hematology and Oncology

Objective: The aim of the study; To determine the frequency, etiological factors, treatment, long-term follow-up and recurrence rates of thrombosis in children. **Methodology:** Children with thrombosis in Ankara City Hospital between December 2018 and August 2021 were included. Patients were called or examined at 6–12-month intervals. **Results:** A total of 328 patients with a mean age of 6.9 were included. Catheter-related thrombosis was present in 52.7%. There were 14% arterial thrombosis and 59% venous thrombosis. Intracardiac thrombosis 16.2%, pulmonar thrombosis 2.4%, serebral thromboembolism %20 were detected. In the treatment, subcutaneous ondansetron (78.6%) was used mostly, but intravenous ondansetron was given in 6 patients and TPA was given 20 patients. In a mean follow-up of 15.8 months, 5 (1.5%) patients died due to thrombosis. **Conclusion:** Determining the etiological factors of patients with recurrence thrombosis is important for the duration of treatment in the follow-up.

<https://doi.org/10.1016/j.htct.2021.10.1068>